The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
Open accessAbstract
OBJECTIVE: A comprehensive meta-analysis of clinical trial data was performed to assess the possible association of fluoxetine and suicidality (suicidal acts and ideation). DESIGN: Retrospective analysis of pooled data from 17 double blind clinical trials in patients with major depressive disorder comparing fluoxetine (n = 1765) with a tricyclic antidepressant (n = 731) or placebo (n = 569), or both. MAIN OUTCOME MEASURES: Multiple data sources were searched to identify patients with suicidal acts. Suicidal ideation was assessed with item 3 of the Hamilton depression rating scale, which systematically rates suicidality. Emergence of substantial suicidal ideation was defined as a change in the rating of this item from 0 or 1 at baseline to 3 or 4 during double blind treatment; worsening was defined as any increase from baseline; improvement was defined as a decrease from baseline at the last visit during the treatment. RESULTS: Suicidal acts did not differ significantly in comparisons of fluoxetine with placebo (0.2% v 0.2%, p = 0.494, Mantel-Haenszel adjusted incidence difference) and with tricyclic antidepressants (0.7% v 0.4%, p = 0.419). The pooled incidence of suicidal acts was 0.3% for fluoxetine, 0.2% for placebo, and 0.4% for tricyclic antidepressants, and fluoxetine did not differ significantly from either placebo (p = 0.533, Pearson's chi 2) or tricyclic antidepressants (p = 0.789). Suicidal ideation emerged marginally significantly less often with fluoxetine than with placebo (0.9% v 2.6%, p = 0.094) and numerically less often than with tricyclic antidepressants (1.7% v 3.6%, p = 0.102). The pooled incidence of emergence of substantial suicidal ideation was 1.2% for fluoxetine, 2.6% for placebo, and 3.6% for tricyclic antidepressants. The incidence was significantly lower with fluoxetine than with placebo (p = 0.042) and tricyclic antidepressants (p = 0.001). Any degree of worsening of suicidal ideation was similar with fluoxetine and placebo (15.4% v 17.9%, p = 0.196) and with fluoxetine and tricyclic antidepressants (15.6% v 16.3%, p = 0.793). The pooled incidence of worsening of suicidal ideation was 15.3% for fluoxetine, 17.9% for placebo, and 16.3% for tricyclic antidepressants. The incidence did not differ significantly with fluoxetine and placebo (p = 0.141) or tricyclic antidepressants (p = 0.542). Suicidal ideation improved significantly more with fluoxetine than with placebo (72.0% v 54.8%, p less than 0.001) and was similar to the improvement with tricyclic antidepressants (72.5% v 69.8%, p = 0.294). The pooled incidence of improvement of suicidal ideation was 72.2% for fluoxetine, 54.8% for placebo, and 69.8% for tricyclic antidepressants. The incidence with fluoxetine was significantly greater than with placebo (p less than 0.001) and did not differ from that with tricyclic antidepressants (p = 0.296). CONCLUSIONS: Data from these trials do not show that fluoxetine is associated with an increased risk of suicidal acts or emergence of substantial suicidal thoughts among depressed patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Time-related predictors of suicide in major affective disorder
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.9.1189 · Cited by 1,058
Suicidal Feelings in the General Population: A Prevalence Study
Paykel, E. S., Myers, J. K., Lindenthal, J. J., & Tanner, J. (1974) · British Journal of Psychiatry · doi:10.1192/bjp.124.5.460 · Cited by 827
Estimation of a Common Effect Parameter from Sparse Follow-Up Data
Greenland, S., & Robins, J. M. (1985) · Biometrics · doi:10.2307/2530643 · Cited by 794
Suicide and Primary Affective Disorders
Guze, S. B., & Robins, E. (1970) · British Journal of Psychiatry · doi:10.1192/bjp.117.539.437 · Cited by 724
Emergence of intense suicidal preoccupation during fluoxetine treatment
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.2.207 · Cited by 532
Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up
Simeon, J. G., Dinicola, V. F., Ferguson, H. B., & Copping, W. (1990) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(90)90050-q · Cited by 264
A Comparison of Fluoxetine Imipramine and Placebo in Patients with Bipolar Depressive Disorder
COHN, J. B., COLLINS, G., ASHBROOK, E., & WERNICKE, J. F. (1989) · International Clinical Psychopharmacology · doi:10.1097/00004850-198910000-00006 · Cited by 257
Panic Disorder, Comorbidity, and Suicide Attempts
Johnson, J. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810210013002 · Cited by 245
Stark, P., & Hardison, C. D. (1985) · PubMed · Cited by 239
Cited by
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
McAuley, L., Pham, B., Tugwell, P., & Moher, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02786-0 · Cited by 812
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
Antidepressants and the Risk of Suicidal Behaviors
Jick, H. (2004) · JAMA · doi:10.1001/jama.292.3.338 · Cited by 578
Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations
Thase, M. E. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230043006 · Cited by 515
Treatment and prevention of depression
Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002) · Psychological Science in the Public Interest · doi:10.1111/1529-1006.00008 · Cited by 511
Bauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., WFSBP Task Force on Unipolar Depres, Bauer, M., Bschor, T., et al. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227829 · Cited by 477
Shaffer, D., & Pfeffer, C. R. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107001-00003 · Cited by 460
Williams, J. W., Mulrow, C. D., Chiquette, E., Noël, P. H., Aguilar, C., & Cornell, J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00011 · Cited by 423
Suicidal Behaviour in Bipolar Disorder: Risk and Prevention
Tondo, L., Isacsson, G., & Baldessarini, R. J. (2003) · CNS Drugs · doi:10.2165/00023210-200317070-00003 · Cited by 402
Khan, A., Khan, S., Kolts, R., & Brown, W. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.790 · Cited by 394
Gunnell, D., Saperia, J., & Ashby, D. (2005) · BMJ · doi:10.1136/bmj.330.7488.385 · Cited by 387
Moher, Cook, Jadad, Tugwell, Moher, Jones, Pham, & Klassen (1999) · Health Technology Assessment · doi:10.3310/hta3120 · Cited by 368
Meta-analytical studies on new antidepressants
Anderson, I. M. (2001) · British Medical Bulletin · doi:10.1093/bmb/57.1.161 · Cited by 351
Akiskal, H. S., Benazzi, F., Perugi, G., & Rihmer, Z. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.12.004 · Cited by 348
Ellenberg, S. S., & Temple, R. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-6-200009190-00015 · Cited by 331
Hollon, S. D., Muñoz, R. F., Barlow, D. H., Beardslee, W. R., Bell, C. C., Bernal, G., Clarke, G. N., Franciosi, L. P., Kazdin, A. E., Kohn, L., et al. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01384-7 · Cited by 328
Users' Guides to the Medical Literature: IV. How to Use an Article About Harm
Levine, M. (1994) · JAMA · doi:10.1001/jama.1994.03510440075037 · Cited by 311
Anderson, I. M., Nutt, D. J., & Deakin, J. F. W. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400101 · Cited by 310
Psychosocial interventions for self-harm in adults
Hawton, K., Witt, K. G., Taylor Salisbury, T. L., Arensman, E., Gunnell, D., Hazell, P., Townsend, E., & van Heeringen, K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012189 · Cited by 310
The Cost–Utility of Screening for Depression in Primary Care
Valenstein, M., Vijan, S., Zeber, J. E., Boehm, K., & Buttar, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-5-200103060-00007 · Cited by 268
Hansen, R. A., Gartlehner, G., Lohr, K. N., Gaynes, B. N., & Carey, T. S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-6-200509200-00006 · Cited by 255
Bipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Suicidal risks among 2826 Sardinian major affective disorder patients
Tondo, L., Lepri, B., & Baldessarini, R. J. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01066.x · Cited by 177
Psychosocial treatments of suicidal behaviors: A practice‐friendly review
Comtois, K. A., & Linehan, M. M. (2006) · Journal of Clinical Psychology · doi:10.1002/jclp.20220 · Cited by 139
Non-suicidal self-injury within offender populations: a systematic review
Dixon-Gordon, K., Harrison, N., & Roesch, R. (2012) · International Journal of Forensic Mental Health · doi:10.1080/14999013.2012.667513 · Cited by 133
Meyer, R. E., Salzman, C., Youngstrom, E. A., Clayton, P. J., Goodwin, F. K., Mann, J. J., Alphs, L. D., Broich, K., Goodman, W. K., Greden, J. F., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10cs06070blu · Cited by 129
Self-citationSuicide, suicidality and suicide prevention in affective disorders
Möller, H. J. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.108.s418.15.x · Cited by 127
Dold, M., Bartova, L., Fugger, G., Kautzky, A., Souery, D., Mendlewicz, J., Papadimitriou, G. N., Dikeos, D., Ferentinos, P., Porcelli, S., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy009 · Cited by 82
Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment
Tondo, L., & Baldessarini, R. J. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0715-0 · Cited by 71
Antidepressants and Suicide Risk: A Comprehensive Overview
Pompili, M., Serafini, G., Innamorati, M., Ambrosi, E., Giordano, G., Girardi, P., Tatarelli, R., & Lester, D. (2010) · Pharmaceuticals · doi:10.3390/ph3092861 · Cited by 53
Judd, F. K., Moore, K., Norman, T. R., Burrows, G. D., Gupta, R. K., & Parker, G. (1993) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679309072123 · Cited by 25
Quality assessment of meta-analyses of RCTs of pharmacotherapy in major depressive disorder.
Hemels, M. E. H., Vicente, C., Sadri, H., Masson, M. J., & Einarson, T. R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003197 · Cited by 23
MOLLER, H. (1994) · European Neuropsychopharmacology · doi:10.1016/0924-977x(94)90315-8 · Cited by 16
Dudley, M., Hadzi-Pavlovic, D., Andrews, D., & Perich, T. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802050538 · Cited by 15
Metadata
- Authors
- Beasley, C. M., Dornseif, B. E., Bosomworth, J. C., Sayler, M. E., Rampey, A. H., Heiligenstein, J. H., Thompson, V. L., Murphy, D. J., & Masica, D. N.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1991-09-21
- Volume
- 303
- Issue
- 6804
- Pages
- 685-692
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W1971916547
- Cited by
- 361
- References
- 34
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.